Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director | September 15, 2020 | September 18, 2020 |
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | 10% owner | January 19, 2023 | January 30, 2023 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | 10% owner | February 24, 2021 | February 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date September 15, 2020 · Filed September 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy aMoon 2 Fund Limited Partnership | 1,104,460 |
Reported balance
After 2020-09-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-09-15 · Grant · Acquired 1,104,460 · Balance 1,104,460 F1: The reporting person is the sole shareholder of aMoon General Partner Ltd., which is the sole general partner of aMoon 2 Fund G.P. Limited Partnership, which is the sole general partner of aMoon 2 Fund Limited Partnership, which directly holds the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. F2: Received in exchange for shares of Series B Preferred Stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, the closing share price of a share of resTORbio common stock was $2.28 per share. On the effective date of the Merger, resTorbio changed its name to "Adicet Bio, Inc." |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.11 · Expires 2030-09-16 | Direct | 30,000 |
Reported balance
After 2020-09-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-17 · Grant · Acquired 30,000 · Balance 30,000 F3: The shares of common stock subject to the option shall vest in equal installments on each of the thirty-six (36) monthly anniversaries of the vesting commencement date, provided that the reporting person remains in continuous service as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the sole shareholder of aMoon General Partner Ltd., which is the sole general partner of aMoon 2 Fund G.P. Limited Partnership, which is the sole general partner of aMoon 2 Fund Limited Partnership, which directly holds the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F2: Received in exchange for shares of Series B Preferred Stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, the closing share price of a share of resTORbio common stock was $2.28 per share. On the effective date of the Merger, resTorbio changed its name to "Adicet Bio, Inc."
F3: The shares of common stock subject to the option shall vest in equal installments on each of the thirty-six (36) monthly anniversaries of the vesting commencement date, provided that the reporting person remains in continuous service as of the applicable vesting date.
Ayala Pharmaceuticals, Inc.
Report date January 19, 2023 · Filed January 30, 2023
Jointly reported with aMoon Growth Fund Limited Partnership
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 560,602 |
Reported balance
Holding disclosure · report date 2023-01-19 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 560,602 F1: The reported shares are held of record by aMoon Growth Fund, Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are held of record by aMoon Growth Fund, Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.
Viracta Therapeutics, Inc.
Report date February 24, 2021 · Filed February 25, 2021
Jointly reported with aMoon Growth Fund Limited Partnership
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,359,372 |
Reported balance
Holding disclosure · report date 2021-02-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,359,372 F1: The reported shares are held of record by aMoon 2 Fund, Limited Partnership ("aMoon 2 Fund"). aMoon 2 Fund G.P. Limited Partnership ("aMoon 2 Fund G.P.") is the sole General Partner of aMoon 2 Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon 2 Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon 2 Fund. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon 2 Fund except to the extent of its or his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,032,865 |
Reported balance
Holding disclosure · report date 2021-02-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,032,865 F2: The reported shares are held of record by aMoon - VRCT SPV Limited Partnership ("aMoon - VRCT"). aMoon 2 Fund G.P. is the sole General Partner of aMoon - VRCT and aMoon General Partner is the sole General Partner of aMoon 2 Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon - VRCT. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon - VRCT except to the extent of its or his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are held of record by aMoon 2 Fund, Limited Partnership ("aMoon 2 Fund"). aMoon 2 Fund G.P. Limited Partnership ("aMoon 2 Fund G.P.") is the sole General Partner of aMoon 2 Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon 2 Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon 2 Fund. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon 2 Fund except to the extent of its or his pecuniary interest therein, if any.
F2: The reported shares are held of record by aMoon - VRCT SPV Limited Partnership ("aMoon - VRCT"). aMoon 2 Fund G.P. is the sole General Partner of aMoon - VRCT and aMoon General Partner is the sole General Partner of aMoon 2 Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon - VRCT. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon - VRCT except to the extent of its or his pecuniary interest therein, if any.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Old Ayala, Inc
Report date January 19, 2023 · Filed January 24, 2023
Jointly reported with aMoon Growth Fund Limited Partnership
Section 16 reporting ended · disclosed 2023-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-01-19 · Disposition to issuer · Disposed 2,991,473 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, upon the consummation of the merger on January 19, 2023, each share of Ayala's common stock was cancelled and converted into the right to receive shares of Advaxis common stock based on the exchange ratio set forth therein. F2: The reported shares were held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, upon the consummation of the merger on January 19, 2023, each share of Ayala's common stock was cancelled and converted into the right to receive shares of Advaxis common stock based on the exchange ratio set forth therein.
F2: The reported shares were held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.
Seer, Inc.
Report date June 09, 2021 · Filed June 11, 2021
Jointly reported with aMoon Growth Fund Limited Partnership
Section 16 reporting ended · disclosed 2021-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 4,112,235 |
Reported balance
After 2021-06-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-06-09 · Sale · Disposed 835,278 · Balance 4,112,235 F1: The reported shares are held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 810,961 |
Reported balance
After 2021-06-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-06-09 · Sale · Disposed 164,722 · Balance 810,961 F2: The reported shares are held of record by aMoon Co-Investment SPV I, L.P. ("aMoon Co-Investment"). aMoon Growth Fund G.P. is the sole General Partner of aMoon Co-Investment and aMoon General Partner is the sole General Partner of aMoon Growth Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Co-Investment. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Co-Investment except to the extent of its or his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.
F2: The reported shares are held of record by aMoon Co-Investment SPV I, L.P. ("aMoon Co-Investment"). aMoon Growth Fund G.P. is the sole General Partner of aMoon Co-Investment and aMoon General Partner is the sole General Partner of aMoon Growth Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Co-Investment. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Co-Investment except to the extent of its or his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2023 Filed Jan 24, 2023 10:21 UTC | Old Ayala, Inc AYLA · Entity 108681 | Disposition to issuerCommon Stock | 2,991,473 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001178913-23-000242 · zk2329064.xml · nonDerivative · entry 1 aMoon Growth Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · shareholder of 10% holder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, upon the consummation of the merger on January 19, 2023, each share of Ayala's common stock was cancelled and converted into the right to receive shares of Advaxis common stock based on the exchange ratio set forth therein. F2 · ownership.direct: The reported shares were held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 06:59 UTC | Seer, Inc. SEER · Entity 6717 | SaleClass A Common Stock | 164,722 | $30.00 | $4,941,660.00 |
DisclosureSEC source: 0001178913-21-002059 · zk2126185.xml · nonDerivative · entry 2 aMoon Growth Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · shareholder of 10% holder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 810,961 F2 · ownership.nature: The reported shares are held of record by aMoon Co-Investment SPV I, L.P. ("aMoon Co-Investment"). aMoon Growth Fund G.P. is the sole General Partner of aMoon Co-Investment and aMoon General Partner is the sole General Partner of aMoon Growth Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Co-Investment. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Co-Investment except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 06:59 UTC | Seer, Inc. SEER · Entity 6717 | SaleClass A Common Stock | 835,278 | $30.00 | $25,058,340.00 |
DisclosureSEC source: 0001178913-21-002059 · zk2126185.xml · nonDerivative · entry 1 aMoon Growth Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · shareholder of 10% holder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,112,235 F1 · ownership.direct: The reported shares are held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 16:15 UTC | Seer, Inc. SEER · Entity 6717 | PurchaseClass A Common Stock | 63,024 | $19.00 | $1,197,456.00 |
DisclosureSEC source: 0001628280-20-017345 · wf-form4_160763491526922.xml · nonDerivative · entry 5 aMoon 2 Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 975,683 F4 · ownership.nature: The reported shares are held of record by aMoon Co-Investment SPV I, L.P. ("aMoon Co-Investment"). aMoon 2 Fund G.P. is the sole General Partner of aMoon Co-Investment and aMoon General Partner is the sole General Partner of aMoon 2 Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Co-Investment. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Co-Investment except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 16:15 UTC | Seer, Inc. SEER · Entity 6717 | PurchaseClass A Common Stock | 726,449 | $19.00 | $13,802,531.00 |
DisclosureSEC source: 0001628280-20-017345 · wf-form4_160763491526922.xml · nonDerivative · entry 3 aMoon 2 Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,947,513 F3 · ownership.direct: The reported shares are held of record by aMoon 2 Fund, Limited Partnership ("aMoon 2 Fund"). aMoon 2 Fund G.P. Limited Partnership ("aMoon 2 Fund G.P.") is the sole General Partner of aMoon 2 Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon 2 Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon 2 Fund. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon 2 Fund except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:15 UTC | Seer, Inc. SEER · Entity 6717 | ConversionSeries D-1 Convertible Preferred Stock · Derivative | 125,279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-20-017345 · wf-form4_160763491526922.xml · derivative · entry 9 aMoon 2 Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 125,279 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F2 · price: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F2 · derivative.exercise_date: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F2 · derivative.expiration_date: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F4 · ownership.nature: The reported shares are held of record by aMoon Co-Investment SPV I, L.P. ("aMoon Co-Investment"). aMoon 2 Fund G.P. is the sole General Partner of aMoon Co-Investment and aMoon General Partner is the sole General Partner of aMoon 2 Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Co-Investment. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Co-Investment except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:15 UTC | Seer, Inc. SEER · Entity 6717 | ConversionSeries D Convertible Preferred Stock · Derivative | 787,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-20-017345 · wf-form4_160763491526922.xml · derivative · entry 8 aMoon 2 Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 787,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F1 · price: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F4 · ownership.nature: The reported shares are held of record by aMoon Co-Investment SPV I, L.P. ("aMoon Co-Investment"). aMoon 2 Fund G.P. is the sole General Partner of aMoon Co-Investment and aMoon General Partner is the sole General Partner of aMoon 2 Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Co-Investment. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Co-Investment except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:15 UTC | Seer, Inc. SEER · Entity 6717 | ConversionSeries D-1 Convertible Preferred Stock · Derivative | 1,245,436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-20-017345 · wf-form4_160763491526922.xml · derivative · entry 7 aMoon 2 Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,245,436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F2 · price: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F2 · derivative.exercise_date: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F2 · derivative.expiration_date: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F3 · ownership.direct: The reported shares are held of record by aMoon 2 Fund, Limited Partnership ("aMoon 2 Fund"). aMoon 2 Fund G.P. Limited Partnership ("aMoon 2 Fund G.P.") is the sole General Partner of aMoon 2 Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon 2 Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon 2 Fund. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon 2 Fund except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:15 UTC | Seer, Inc. SEER · Entity 6717 | ConversionSeries D Convertible Preferred Stock · Derivative | 2,875,628 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-20-017345 · wf-form4_160763491526922.xml · derivative · entry 6 aMoon 2 Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,875,628 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F1 · price: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F3 · ownership.direct: The reported shares are held of record by aMoon 2 Fund, Limited Partnership ("aMoon 2 Fund"). aMoon 2 Fund G.P. Limited Partnership ("aMoon 2 Fund G.P.") is the sole General Partner of aMoon 2 Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon 2 Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon 2 Fund. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon 2 Fund except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:15 UTC | Seer, Inc. SEER · Entity 6717 | ConversionClass A Common Stock | 912,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-20-017345 · wf-form4_160763491526922.xml · nonDerivative · entry 4 aMoon 2 Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 912,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F2 · price: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F4 · ownership.nature: The reported shares are held of record by aMoon Co-Investment SPV I, L.P. ("aMoon Co-Investment"). aMoon 2 Fund G.P. is the sole General Partner of aMoon Co-Investment and aMoon General Partner is the sole General Partner of aMoon 2 Fund G.P. Dr. Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon Co-Investment. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Co-Investment except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:15 UTC | Seer, Inc. SEER · Entity 6717 | PurchaseClass A Common Stock | 100,000 | $19.00 | $1,900,000.00 |
DisclosureSEC source: 0001628280-20-017345 · wf-form4_160763491526922.xml · nonDerivative · entry 2 aMoon 2 Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,221,064 F3 · ownership.direct: The reported shares are held of record by aMoon 2 Fund, Limited Partnership ("aMoon 2 Fund"). aMoon 2 Fund G.P. Limited Partnership ("aMoon 2 Fund G.P.") is the sole General Partner of aMoon 2 Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon 2 Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon 2 Fund. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon 2 Fund except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:15 UTC | Seer, Inc. SEER · Entity 6717 | ConversionClass A Common Stock | 4,121,064 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-20-017345 · wf-form4_160763491526922.xml · nonDerivative · entry 1 aMoon 2 Fund Limited Partnership · CIK 0001744099 · 10% owner Schindel Yair Chaim · CIK 0001823758 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,121,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series D Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F2 · price: Each share of Series D-1 Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F3 · ownership.direct: The reported shares are held of record by aMoon 2 Fund, Limited Partnership ("aMoon 2 Fund"). aMoon 2 Fund G.P. Limited Partnership ("aMoon 2 Fund G.P.") is the sole General Partner of aMoon 2 Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon 2 Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel may be deemed to have shared voting and investment power with respect to the shares held of record by aMoon 2 Fund. Each of aMoon 2 Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon 2 Fund except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:55 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0000899243-20-025654 · doc4.xml · derivative · entry 2 Schindel Yair Chaim · CIK 0001823758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-09-16 F3 · derivative.exercise_date: The shares of common stock subject to the option shall vest in equal installments on each of the thirty-six (36) monthly anniversaries of the vesting commencement date, provided that the reporting person remains in continuous service as of the applicable vesting date. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:55 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 1,104,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-025654 · doc4.xml · nonDerivative · entry 1 Schindel Yair Chaim · CIK 0001823758 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By aMoon 2 Fund Limited Partnership Disclosed balance after: 1,104,460 F1 · shares: The reporting person is the sole shareholder of aMoon General Partner Ltd., which is the sole general partner of aMoon 2 Fund G.P. Limited Partnership, which is the sole general partner of aMoon 2 Fund Limited Partnership, which directly holds the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. F2 · price: Received in exchange for shares of Series B Preferred Stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, the closing share price of a share of resTORbio common stock was $2.28 per share. On the effective date of the Merger, resTorbio changed its name to "Adicet Bio, Inc." Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.